34
Participants
Start Date
June 9, 2020
Primary Completion Date
April 30, 2021
Study Completion Date
April 30, 2021
COVID-19 Convalescent Plasma (CCP)
COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the purpose of preventing or treating the infectious disease it causes. Convalescent plasma for this trial will be obtained from Vitalant (or American Red Cross if necessary). Patients identified as having recovered from COVID-19 will serve as potential donors. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined.
Placebo
Standard plasma will be obtained from Vitalant (or American Red Cross if necessary) and will be either collected prior to 12/1/2019 or tested and confirmed to be negative for anti-SARS-CoV-2.
San Francisco General Hospital, San Francisco
UCSF Medical Center at Mount Zion, San Francisco
University of California, San Francisco Medical Center (Parnassus Campus), San Francisco
Vitalant Research Institute
OTHER
San Francisco General Hospital
OTHER
Priscilla Hsue, MD
OTHER